Viral Coinfections in Children With Invasive Pneumococcal Disease

Background: Respiratory viruses contribute to the seasonal pattern of invasive pneumococcal disease (IPD), but the impact of viral coinfections on the clinical characteristics and outcomes of patients with IPD have not been well defined. Objective: This study was designed to describe and compare the clinical presentations and outcomes of patients with IPD with or without viral coinfections. Design/Methods: Retrospective analyses of records of all children treated at Children's Medical Center Dallas (CMCD) for IPD from July 2005 to June 2008. Viral studies included viral direct fluorescent antibody staining and culture. For comparisons, patients were classified in 3 groups: with positive, negative, and no viral studies performed. Results: A total of 129 patients were admitted to CMCD with IPD during the 3 year study; 57% were male. Ages ranged from 2 months to 18 years (median 25 months) and 48% were <2 years. Viral studies were performed in 82 (63%) patients, and 28 (34%) had positive results. The most common viruses isolated were influenza (7, 25%), rhinoviruses (6, 21%), adenoviruses (6, 21%), and RSV (5, 18%). Peaks of positive viral studies occurred in February and November which coincided with the peak numbers of patients admitted with IPD. Of 6 with adenovirus coinfection, 5 were admitted to Pediatric Intensive Care Unit (PICU). The most common pneumococcal serotypes were 19A (41, 32.5%), 7F (14, 11%), and 23A (13, 10.3%). Pneumonia (42%), bacteremia (22%), and meningitis (17%) were the most common clinical syndromes. There were no differences in duration of fever before admission, maximum temperatures during hospitalization and white blood cell counts, duration of fever and hospitalization between patients with positive and negative viral studies, but there was a trend for patient with positive viral studies to be admitted to PICU more frequently and to have longer PICU stay. Three of the 6 patients who died had documented viral coinfections (2 adenovirus, 1 parainfluenza 3), and all 3 had no underlying conditions. The other 3 patients who died had no viral studies performed. Duration of treatment ranged from 1 to –210 days (median 14), with no differences among the groups. Conclusions: Viral coinfections were common in children with IPD. Future prospective studies should include new PCR assays to characterize better the impact of viral coinfections in the occurrence and outcome of IPD.

[1]  D. Metzgar,et al.  Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. , 2009, The Journal of infectious diseases.

[2]  P. Cieslak,et al.  A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. , 2009, The Journal of infectious diseases.

[3]  C. Bonville,et al.  Clinical Features, Adenovirus Types, and Local Production of Inflammatory Mediators in Adenovirus Infections , 2009, The Pediatric infectious disease journal.

[4]  Philip M Polgreen,et al.  Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. , 2009, Annals of emergency medicine.

[5]  L. Brammer,et al.  Influenza-Associated Pediatric Mortality in the United States: Increase of Staphylococcus aureus Coinfection , 2008, Pediatrics.

[6]  G. Dennis Shanks,et al.  Deaths from Bacterial Pneumonia during 1918–19 Influenza Pandemic , 2008, Emerging infectious diseases.

[7]  C. Byington,et al.  Seasonal Invasive Pneumococcal Disease in Children: Role of Preceding Respiratory Viral Infection , 2008, Pediatrics.

[8]  E. Simões,et al.  Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Eichelberger,et al.  Co-infection of the cotton rat (Sigmodon hispidus) with Staphylococcus aureus and influenza A virus results in synergistic disease. , 2007, Microbial pathogenesis.

[10]  W. Edmunds,et al.  The contribution of respiratory pathogens to the seasonality of NHS Direct calls , 2007, Journal of Infection.

[11]  D. Rasko,et al.  Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005 , 2007, The Pediatric infectious disease journal.

[12]  A. Lahad,et al.  Does pneumococcal vaccine reduce influenza morbidity in humans? , 2007, Vaccine.

[13]  D. Fisman,et al.  Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. , 2007, Archives of internal medicine.

[14]  O. Ruuskanen,et al.  Respiratory viruses in children with invasive pneumococcal disease. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. McCullers.  Insights into the Interaction between Influenza Virus and Pneumococcus , 2006, Clinical Microbiology Reviews.

[16]  A. Torres,et al.  Mixed community-acquired pneumonia in hospitalised patients , 2006, European Respiratory Journal.

[17]  T. van der Poll,et al.  Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. , 2006, The Journal of infectious diseases.

[18]  W. Schaffner,et al.  Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. , 2005, The American journal of medicine.

[19]  M. Griffin,et al.  Epidemiology of Respiratory Infections in Young Children: Insights from the New Vaccine Surveillance Network , 2004, The Pediatric infectious disease journal.

[20]  T. van der Poll,et al.  IL-10 Is an Important Mediator of the Enhanced Susceptibility to Pneumococcal Pneumonia after Influenza Infection , 2004, The Journal of Immunology.

[21]  Kurt Olsen,et al.  Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. , 2004, Pediatrics.

[22]  A. Schuchat,et al.  Seasonal Patterns of Invasive Pneumococcal Disease , 2003, Emerging infectious diseases.

[23]  J. McCullers,et al.  Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. , 2003, The Journal of infectious diseases.

[24]  J. Rehg,et al.  Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. , 2002, The Journal of infectious diseases.

[25]  K. O'Brien,et al.  Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  A. Hakansson,et al.  Adenovirus infection enhances in vitro adherence of Streptococcus pneumoniae , 1994, Infection and immunity.

[27]  J. Nelson,et al.  Possible association of mycoplasma and viral respiratory infections with bacterial meningitis. , 1987, American journal of epidemiology.

[28]  M. Degré,et al.  BACTERIAL MENINGITIS AFTER INFLUENZA , 1982, The Lancet.

[29]  A. Frank,et al.  Nasopharyngeal viral isolates in children with Haemophilusinfluenzae type B meningitis† , 1981, The Journal of Pediatrics.

[30]  Kjellstrand Cm.  THE HUNT FOR RENAL HYPERTENSION , 1976 .

[31]  J. Stockman.  Influenza-Associated Pediatric Mortality in the United States: Increase of Staphylococcus aureus Coinfection , 2010 .

[32]  T. van der Poll,et al.  Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[33]  D. Musher,et al.  Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.